BioInvent International AB logo

BINV BTA - BioInvent International AB News Story

SEK1.7 0.0  0.0%

Last Trade - 12/08/20

Sector
Healthcare
Size
Small Cap
Market Cap £268.0m
Enterprise Value £135.6m
Revenue £11.6m
Position in Universe th / 1830

BRIEF-Transgene And Bioinvent Receive CTA Approval For Phase 1/2A Trial Of Oncolytic Virus BT-001 In Solid Tumors

Mon 21st December, 2020 7:34am
Dec 21 (Reuters) - Transgene  TRNG.PA :
    * TRANSGENE AND BIOINVENT RECEIVE CTA APPROVAL FOR PHASE
1/2A
TRIAL OF ONCOLYTIC VIRUS BT-001 IN SOLID TUMORS

Source text for Eikon:  ID:nBw4JyDTBa 
Further company coverage:  BINV.ST ,  TRNG.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.